share_log

智飞生物四价流感病毒裂解疫苗获批上市

Chongqing Zhifei Biological Products' quadrivalent influenza virus split vaccine has been approved for marketing.

Breakings ·  Mar 21 13:28

On March 21, the quadrivalent influenza virus split vaccine, a Biological Product independently developed by Anhui Zhifei Longkema, a wholly-owned subsidiary of Chongqing Zhifei Biological Products, received the "Drug Registration Certificate" issued by the National Medical Products Administration. This vaccine is intended for individuals aged 3 and older.

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Comment Comment · Views 212

Recommended

Write a comment

Statement

This page is machine-translated. Futubull tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.